7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications

Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications

Type 2 Diabetes Mellitus (T2DM) is a chronic, progressive, multi-system metabolic disorder characterized by peripheral insulin resistance, progressive pancreatic $\beta$-cell secretory failure, accelerated hepatic gluconeogenesis, and systemic low-grade inflammation. The disease accounts for over 90% of all diagnosed diabetes cases across adult and geriatric populations in the United States. Uncontrolled hyperglycemia drives widespread vascular endothelial injury, making T2DM the leading cause of new-onset end-stage renal disease (ESRD), non-traumatic lower-extremity amputations, and adult-onset blindness, while conferring a two- to four-fold increase in atherosclerotic cardiovascular morbidity and mortality.

For the Adult-Gerontology Primary Care Nurse Practitioner (AGPCNP), board certification demands mastery of current American Diabetes Association (ADA) Standards of Care in Diabetes, including precise diagnostic criteria, individualized glycemic goals, organ-protective pharmacotherapy selection algorithms, insulin initiation and titration mechanics, and proactive microvascular surveillance protocols.

---

1. Pathophysiology: The Ominous Octet & Metabolic Derangements

Historically conceptualized as a dual defect of muscle insulin resistance and $\beta$-cell exhaustion, modern diabetology recognizes the multi-organ pathophysiological schema known as DeFronzo's "Ominous Octet" (further expanded to the Egregious Eleven):

+---------------------------------------------------------------------------------------------------+
|                                 THE OMINOUS OCTET OF TYPE 2 DIABETES                             |
|                                                                                                   |
|   1. PANCREATIC BETA-CELLS   ---> Progressive loss of mass and secretory dysfunction (insulopenia)|
|   2. SKELETAL MUSCLE         ---> Impaired GLUT-4 translocation; diminished glucose uptake        |
|   3. LIVER                   ---> Unchecked hepatic gluconeogenesis and glycogenolysis            |
|   4. ADIPOCYTES              ---> Accelerated lipolysis; elevated circulating free fatty acids   |
|   5. GASTROINTESTINAL TRACT  ---> Diminished incretin effect (GLP-1 & GIP deficiency/resistance)  |
|   6. PANCREATIC ALPHA-CELLS  ---> Hyperglucagonemia driving postprandial hepatic glucose output   |
|   7. KIDNEYS                 ---> Upregulated SGLT2 cotransporters; increased glucose reabsorption|
|   8. BRAIN / HYPOTHALAMUS    ---> Neurotransmitter dysregulation, altered appetite and satiety   |
+---------------------------------------------------------------------------------------------------+

Metabolic Synergies & Glucolipotoxicity

1. Insulin Resistance (Receptor and Post-Receptor Defects): Defective tyrosine kinase autophosphorylation of the insulin receptor and impaired intracellular signaling cascades (IRS-1, PI3K, Akt) inhibit the mobilization of glucose transporter type 4 (GLUT-4) vesicles to the cell membranes of skeletal muscle and adipose tissue. This results in severe impairment of postprandial glucose disposal.
2. Hepatic Overproduction: In the fasting state, hepatic insulin resistance uncouples the normal inhibitory feedback on gluconeogenesis and glycogenolysis, mediated by unchecked phosphoenolpyruvate carboxykinase (PEPCK) activity, producing elevated fasting plasma glucose levels.
3. Lipotoxicity & $\beta$-Cell Apoptosis: Excess visceral adiposity causes chronic release of non-esterified free fatty acids (FFAs) and inflammatory adipokines (TNF-$\alpha$, IL-6, resistin). Ectopic lipid accumulation in pancreatic islets triggers endoplasmic reticulum stress, mitochondrial dysfunction, and accelerated $\beta$-cell apoptosis. By the time clinical fasting hyperglycemia manifests, approximately 50% of functional $\beta$-cell mass has already been irrevocably lost.
4. Incretin Dysfunction: The "incretin effect"—the physiological phenomenon whereby oral glucose stimulates substantially greater insulin secretion than an equivalent intravenous glucose load—is blunted or absent in T2DM due to impaired intestinal secretion and accelerated enzymatic degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) by dipeptidyl peptidase-4 (DPP-4).

---

2. ADA Diagnostic Criteria, Screening Recommendations & Hemoglobin A1c Nuances

+---------------------------------------------------------------------------------------------------+
|                             ADA DIAGNOSTIC THRESHOLDS FOR GLYCEMIC STATUS                         |
|                                                                                                   |
|   DIAGNOSTIC TEST              NORMAL             PRE-DIABETES              DIABETES MELLITUS     |
|   ---------------------------------------------------------------------------------------------   |
|   Fasting Plasma Glucose (FPG) < 100 mg/dL        100 - 125 mg/dL           >= 126 mg/dL          |
|   2-Hour 75g OGTT              < 140 mg/dL        140 - 199 mg/dL           >= 200 mg/dL          |
|   Hemoglobin A1c (HbA1c)       < 5.7%             5.7% - 6.4%               >= 6.5%               |
|   Random Plasma Glucose        --                 --                        >= 200 mg/dL WITH     |
|                                                                             classic symptoms*     |
|                                                                                                   |
|   *Classic Symptoms: Polyuria, polydipsia, polyphagia, unexplained weight loss, hyperglycemic crisis|
+---------------------------------------------------------------------------------------------------+

Critical Diagnostic Protocols:

• Asymptomatic Patient Confirmation: In the absence of unequivocal symptomatic hyperglycemia (e.g., polyuria, polydipsia, weight loss) or acute hyperglycemic crisis, a diagnosis of diabetes requires two abnormal test results from either the same sample or two separate test samples (e.g., FPG ≥126 mg/dL and HbA1c ≥6.5% from the same blood draw, or repeat testing on a subsequent clinical encounter).
• Discordant Results: If two different tests (e.g., FPG and HbA1c) are discordant, the test that is above the diagnostic threshold must be repeated, and the diagnosis is confirmed if the repeat value remains abnormal.

Population Screening Guidelines (USPSTF & ADA):

• Universal Screening: Screen all asymptomatic non-pregnant adults beginning at age 35 (USPSTF Grade B; ADA recommends universal screening at age 35 for all individuals). Repeat testing at a minimum of 3-year intervals if results are normal.
• Risk-Based Screening (Any Age): Screen adults of any age who are overweight or obese ($\text{BMI} \ge 25\text{ kg/m}^2$, or $\ge 23\text{ kg/m}^2$ in Asian Americans) who exhibit one or more additional risk factors:
  • First-degree relative with diabetes (parent or sibling).
  • High-risk race/ethnicity (African American, Hispanic/Latino, American Indian, Asian American, Pacific Islander).
  • History of Cardiovascular Disease (ASCVD).
  • Hypertension ($\ge 130/80\text{ mmHg}$ or on antihypertensive therapy).
  • Dyslipidemia ($\text{HDL-C} < 35\text{ mg/dL}$ and/or fasting triglycerides $> 250\text{ mg/dL}$).
  • History of Polycystic Ovary Syndrome (PCOS) or gestational diabetes mellitus (GDM).
  • Physical inactivity / sedentary lifestyle.
  • Conditions associated with severe insulin resistance (e.g., severe obesity, acanthosis nigricans).
  • Pre-diabetes on prior testing (screen annually).
  • Individuals with HIV (screen before starting antiretroviral therapy and at 3–6 month intervals).

Clinical Traps & Confounding Factors in HbA1c Measurement

Hemoglobin A1c quantifies the non-enzymatic glycation of the N-terminal valine of the hemoglobin $\beta$-chain over the erythrocyte lifespan (~120 days). Any condition altering erythrocyte turnover will introduce significant diagnostic artifacts:

---

3. Individualized Glycemic Targets Across the Adult-Gerontology Lifespan

The ADA emphasizes individualization of glycemic goals based on patient age, life expectancy, comorbid conditions, micro/macrovascular disease burden, and hypoglycemia risk profile.

+---------------------------------------------------------------------------------------------------+
|                         GLYCEMIC TARGET STRATIFICATION (ADA STANDARDS)                            |
|                                                                                                   |
|   CLINICAL PROFILE                      HbA1c TARGET     FASTING GLUCOSE     BEDTIME GLUCOSE      |
|   ---------------------------------------------------------------------------------------------   |
|   Healthy Non-Pregnant Adults           < 7.0%           80 - 130 mg/dL      100 - 180 mg/dL      |
|   Younger / Short Duration / No CVD     < 6.5%           80 - 120 mg/dL      100 - 140 mg/dL      |
|   Older Adults: Intact / Few Comorbid   < 7.0 - 7.5%     80 - 130 mg/dL      100 - 180 mg/dL      |
|   Older Adults: Complex / Intermediate  < 8.0%           90 - 150 mg/dL      100 - 180 mg/dL      |
|   Older Adults: Very Complex / Frail    < 8.5% (or avoid 100 - 180 mg/dL     110 - 200 mg/dL      |
|   / End-Stage / Nursing Home            hypoglycemia)                                             |
+---------------------------------------------------------------------------------------------------+

Clinical Nuances of Glycemic Goals in Older Adults:

• Avoiding Overtreatment and Iatrogenic Hypoglycemia: In older adults ($\ge 65\text{ years}$), severe hypoglycemia is associated with acute myocardial infarction, fatal ventricular arrhythmias, sudden cognitive collapse, and catastrophic fall-related hip fractures. When complex, frail older adults or patients with dementia are managed on sulfonylureas or insulin with HbA1c values $<6.5%$, the AGPCNP must actively de-intensify (deprescribe) therapy by tapering sulfonylureas or relaxing basal insulin doses.
• Continuous Glucose Monitoring (CGM) Metrics: In patients utilizing CGM, target Time in Range (TIR, 70–180 mg/dL) > 70%, with Time Below Range (TBR, <70 mg/dL) < 4%, and Time < 54 mg/dL < 1%. For older or high-risk frail individuals, the target is adjusted to TIR > 50% and TBR (<70 mg/dL) < 1%.

---

4. Comprehensive Pharmacotherapy: Cardiorenal Risk-First Treatment Algorithm

The contemporary ADA algorithm decouples pharmacotherapy selection from initial HbA1c levels, prioritizing compelling organ-protective indications (Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease) at the moment of diagnosis.

+---------------------------------------------------------------------------------------------------+
|                    ADA CARDIORENAL RISK-FIRST PHARMACOTHERAPY SELECTION                           |
|                                                                                                   |
|                     [ESTABLISHED T2DM DIAGNOSIS + LIFESTYLE MODIFICATION]                         |
|                                              |                                                    |
|        +-------------------------------------+-------------------------------------+              |
|        |                                                                           |              |
|        v                                                                           v              |
|  [HIGH CARDIORENAL RISK PRESENT]                                          [NO HIGH CARDIORENAL]   |
|  (Established ASCVD, HF, or CKD)                                          [RISK PRESENT]          |
|        |                                                                           |              |
|   +----+--------------------------+-----------------------+                        v              |
|   |                               |                       |              [METFORMIN OR GLP-1 RA /]|
|   v                               v                       v              [SGLT2i BASED ON EFFICACY]|
|  [ESTABLISHED ASCVD /]      [HEART FAILURE]         [CHRONIC KIDNEY]     - Prioritize Weight Loss |
|  [HIGH ASCVD RISK]          (HFrEF or HFpEF)        [DISEASE (CKD)]        (Tirzepatide, Sema)    |
|   * GLP-1 RA with proven     * SGLT2 inhibitor       * SGLT2 inhibitor    - Prioritize Cost /     |
|     CVD benefit (Sema,         (Empa, Dapa, or         (Empa, Dapa, or      Access (Sulfonylurea, |
|     Dula, Liraglutide)         Bexagliflozin)          Cana) with eGFR      TZD, Generic DPP-4i)  |
|          OR                      proven benefit        20-60 or UACR >=30   - Prioritize Minimal  |
|   * SGLT2 inhibitor with               +                       +              Hypoglycemia Risk   |
|     proven CVD benefit       * Add GLP-1 RA if       * If SGLT2i not        (DPP-4i, TZD, SGLT2i, |
|     (Empa, Cana, Dapa)         HbA1c above goal        tolerated/at goal:     GLP-1 RA)           |
|   * Combine both if                                    Add GLP-1 RA                               |
|     needed for goal                                    or Finerenone                              |
+---------------------------------------------------------------------------------------------------+

Comprehensive Antihyperglycemic Drug Comparison Matrix

[!IMPORTANT] Board Exam Pharmacology Traps:

1. GLP-1 RA + DPP-4i Co-prescription: Never prescribe a DPP-4 inhibitor (e.g., sitagliptin) concurrently with a GLP-1 receptor agonist (e.g., semaglutide). They share overlapping incretin pathways; clinical trials demonstrate no additive HbA1c reduction while multiplying adverse effect liability.
2. Euglycemic DKA (euDKA) with SGLT2i: SGLT2 inhibitors can induce severe ketoacidosis with normal or minimally elevated blood glucose levels (<250 mg/dL). SGLT2i must be discontinued at least 3 to 4 days prior to any major elective surgery or extreme endurance athletics, and ketone testing (blood $\beta$-hydroxybutyrate) must be executed if patients present with nausea, malaise, or dyspnea regardless of fingerstick glucose levels.
3. Linagliptin Advantage: Linagliptin (Tradjenta) is the only DPP-4 inhibitor eliminated primarily via the enterohepatic biliary system, requiring zero dose adjustment across all stages of renal impairment.

---

5. Insulin Therapy: Initiation, Titration Algorithms & Physiological Phenomena

+---------------------------------------------------------------------------------------------------+
|                         BASAL-BOLUS INSULIN INITIATION & TITRATION PROTOCOL                       |
|                                                                                                   |
|   [STEP 1: INITIATE BASAL INSULIN]                                                                |
|   - Agents: Glargine (Lantus/Toujeo), Detemir (Levemir), Degludec (Tresiba), or NPH                |
|   - Starting Dose: 10 units daily OR 0.1 - 0.2 units/kg/day administered at bedtime or morning    |
|                                     |                                                             |
|                                     v                                                             |
|   [STEP 2: TITRATE BASAL TO FASTING TARGET (80 - 130 mg/dL)]                                      |
|   - "Treat-to-Target": Increase dose by 2 units every 3 days until fasting glucose in target range|
|   - If fasting hypoglycemia (<70 mg/dL): Immediately reduce basal dose by 10 - 20% (or 2-4 units)|
|   - "Overbasalization Alert": If Basal dose > 0.5 units/kg/day without achieving HbA1c control,   |
|     STOP escalating basal and initiate prandial (bolus) coverage!                                 |
|                                     |                                                             |
|                                     v                                                             |
|   [STEP 3: ADD PRANDIAL (MEALTIME / BOLUS) INSULIN]                                               |
|   - Agents: Rapid-acting analogs (Lispro/Humalog, Aspart/Novolog, Glulisine/Apidra) or Regular    |
|   - Starting Dose: 4 units OR 10% of basal dose administered immediately (0-15 min) before meal   |
|   - Progression: Start with largest meal of the day ("Basal-Plus"); advance to "Basal-Bolus"    |
|     (prandial before each of 3 meals) if HbA1c remains above target.                              |
+---------------------------------------------------------------------------------------------------+

Dawn Phenomenon vs. Somogyi Effect: Diagnostic Differentiation

When a diabetic patient presents with unexplained, persistent early morning fasting hyperglycemia (7:00 AM blood glucose 200–260 mg/dL), the AGPCNP must differentiate between two distinct physiological phenomena by ordering a 3:00 AM capillary blood glucose check:

+---------------------------------------------------------------------------------------------------+
|                        DAWN PHENOMENON VS. SOMOGYI EFFECT DIFFERENTIATION                         |
|                                                                                                   |
|                      [MORNING FASTING HYPERGLYCEMIA (e.g., 220 mg/dL)]                            |
|                                              |                                                    |
|                                              v                                                    |
|                              [CHECK 3:00 AM BLOOD GLUCOSE]                                        |
|                                              |                                                    |
|                       +----------------------+----------------------+                             |
|                       |                                             |                             |
|                       v                                             v                             |
|              [3:00 AM HYPERGLYCEMIC]                       [3:00 AM HYPOGLYCEMIC]                 |
|             (e.g., 140 - 180 mg/dL)                       (e.g., 40 - 60 mg/dL)                   |
|                       |                                             |                             |
|                       v                                             v                             |
|               = DAWN PHENOMENON                              = SOMOGYI EFFECT                     |
|   - Pathophysiology: Physiological surge of       - Pathophysiology: Rebound hyperglycemia driven |
|     nocturnal Growth Hormone, Cortisol, and         by counter-regulatory hormones (epinephrine,  |
|     Glucagon stimulating hepatic gluconeogenesis.   glucagon, cortisol) following nocturnal low.  |
|   - Clinical Action: INCREASE bedtime basal       - Clinical Action: DECREASE bedtime basal       |
|     insulin dose OR shift NPH to bedtime.           insulin dose OR give bedtime protein snack.   |
+---------------------------------------------------------------------------------------------------+

---

6. Microvascular Complications: Surveillance & Evidence-Based Management

+---------------------------------------------------------------------------------------------------+
|                        MICROVASCULAR COMPLICATION SURVEILLANCE TIMELINE                           |
|                                                                                                   |
|   COMPLICATION         SCREENING MODALITY               FREQUENCY        DIAGNOSTIC THRESHOLD     |
|   ---------------------------------------------------------------------------------------------   |
|   Nephropathy (DKD)    Spot Urine Albumin/Creatinine    Annual           UACR >= 30 mg/g          |
|                        Ratio (UACR) + Serum eGFR        (At diagnosis)   eGFR < 60 mL/min         |
|   Retinopathy          Dilated Eye Exam by              Annual           Microaneurysms, cotton   |
|                        Optometrist / Ophthalmologist    (At diagnosis)   wool spots, neovasc.     |
|   Peripheral           10g Semmes-Weinstein Mono-       Annual           Loss of protective       |
|   Neuropathy (DSPN)    filament + 128Hz Tuning Fork     (At diagnosis)   sensation (>=2 sites)    |
|   Autonomic            Orthostatic vitals, Resting HR,  Annual           Orthostatic drop, resting|
|   Neuropathy           GI / GU / erectile review        (At diagnosis)   tachycardia (>100 bpm)   |
|   Comprehensive        Visual inspection, pulses,       Annual           Ulcers, calluses, loss   |
|   Foot Examination     monofilament, pedal deformity    (Every visit*)   of sensation, ABI <0.90  |
|                                                                                                   |
|   *Visual foot inspection should be conducted at every routine diabetes clinical encounter.       |
+---------------------------------------------------------------------------------------------------+

A. Diabetic Kidney Disease (DKD)

• Diagnostic Staging via Albuminuria:
  • Normal: $\text{UACR} < 30\text{ mg/g}$.
  • Microalbuminuria (Moderately Increased): $\text{UACR } 30\text{--}299\text{ mg/g}$.
  • Macroalbuminuria (Severely Increased / Overt Nephropathy): $\text{UACR } \ge 300\text{ mg/g}$.
• Mandatory Diagnostic Protocol: Two of three spot UACR specimens collected within a 3- to 6-month period must be elevated to confirm DKD (due to transient spikes from exercise, infection, fever, or severe hypertension).
• Four Pillars of DKD Pharmacotherapy:
  1. ACE Inhibitor or ARB: Titrated to maximum tolerated dose if UACR $\ge 30\text{ mg/g}$. (Do NOT combine ACEi + ARB).
  2. SGLT2 Inhibitor (Empagliflozin, Dapagliflozin, Canagliflozin): Initiate in all patients with $\text{eGFR } 20\text{--}60\text{ mL/min}$ or $\text{UACR } \ge 30\text{ mg/g}$ to retard GFR decline and ESRD progression.
  3. Non-Steroidal Mineralocorticoid Receptor Antagonist (Finerenone / Kerendia): Indicated for persistent albuminuria ($\text{UACR } \ge 30\text{ mg/g}$) on maximally tolerated ACEi/ARB and SGLT2i with $\text{eGFR } \ge 25\text{ mL/min}$ and serum potassium $\le 5.0\text{ mEq/L}$ (FIDELIO-DKD / FIGARO-DKD trials).
  4. Strict Blood Pressure & Glycemic Control: BP target $<130/80\text{ mmHg}$; HbA1c individualized (~7.0%).

B. Diabetic Retinopathy

• Epidemiology & Screening: Diabetic retinopathy is the leading cause of blindness in working-age adults. In T2DM, screen with a comprehensive dilated eye exam at the time of diagnosis and annually thereafter. (If exams are normal and glycemia is well-controlled, screening may occur every 2 years).
• Stages:
  • Non-Proliferative Diabetic Retinopathy (NPDR): Microaneurysms, dot-and-blot hemorrhages, hard lipid exudates, macular edema (primary cause of visual loss), and cotton wool spots (nerve fiber layer micro-infarctions).
  • Proliferative Diabetic Retinopathy (PDR): Characterized by pathological neovascularization (fragile new blood vessels stimulated by VEGF ischemia) extending into the vitreous, vitreous hemorrhage, preretinal hemorrhage, and tractional retinal detachment.
• Therapy: Intravitreal anti-VEGF agents (aflibercept, ranibizumab, bevacizumab), panretinal laser photocoagulation (PRP), and vitrectomy.

C. Diabetic Peripheral Neuropathy (Distal Symmetric Polyneuropathy - DSPN)

• Clinical Presentation: Classic "stocking-glove" distribution beginning in the distal toes and ascending bilaterally. Positive symptoms (burning, stabbing dysesthesias, hyperalgesia, allodynia) and negative symptoms (numbness, loss of proprioception, sensory ataxia).
• Physical Examination: Annual evaluation using the 10g Semmes-Weinstein Monofilament across plantar surfaces (loss of sensation at $\ge 2$ sites indicates loss of protective sensation and high ulceration risk), combined with testing of vibration perception using a 128-Hz tuning fork, pinprick sensation, and Achilles deep tendon reflexes (early loss of ankle jerks).
• Pharmacological Pain Management (FDA-Approved):
  • Duloxetine (Cymbalta): 60 mg daily (SNRI; also manages comorbid depressive symptoms; avoid in severe hepatic/renal impairment).
  • Pregabalin (Lyrica): 150–300 mg/day divided BID/TID ($\alpha_2\text{-}\delta$ calcium channel ligand; dose-dependent sedation, peripheral edema, renally cleared).
  • Gabapentin (Neurontin): 300–1,800 mg/day divided TID (off-label first-line; sedation, dizziness).
  • Capsaicin 8% Topical Patch or Pregabalin/Duloxetine combinations for refractory pain. (Note: Opioids and tramadol should be strictly avoided due to addiction liability and lack of long-term efficacy).

D. Diabetic Autonomic Neuropathy (DAN)

• Cardiovascular Autonomic Neuropathy (CAN): Resting tachycardia ($>100\text{ bpm}$), fixed heart rate unvarying with deep respiration, orthostatic hypotension (drop in $\text{SBP} \ge 20\text{ mmHg}$ or $\text{DBP} \ge 10\text{ mmHg}$ on standing), painless ("silent") myocardial infarction.
• Diabetic Gastroparesis: Delayed gastric emptying in the absence of mechanical obstruction. Symptoms: early satiety, postprandial fullness, severe nausea, intractable vomiting of undigested food, erratic glycemic control with frequent unexplained postprandial hypoglycemia. Diagnosis: Gastric Emptying Scintigraphy using a radiolabeled solid meal (retention $>10%$ at 4 hours is diagnostic). Treatment: small frequent low-fat/low-fiber meals, optimization of blood glucose, oral Metoclopramide (Reglan - limit to $<12\text{ weeks}$ due to black box warning for tardive dyskinesia), oral Erythromycin (motilin receptor agonist for acute flares), and antiemetics.
• Genitourinary Autonomic Neuropathy: Diabetic cystopathy (atonic bladder, sensory loss of bladder fullness, overflow urinary incontinence, high post-void residuals predisposing to recurrent UTIs), erectile dysfunction (PDE-5 inhibitors: sildenafil, tadalafil), retrograde ejaculation.

---

7. Hyperglycemic Crises: DKA vs. Hyperosmolar Hyperglycemic State (HHS)

+---------------------------------------------------------------------------------------------------+
|                         ACUTE HYPERGLYCEMIC CRISIS DECISION MATRIX                                |
|                                                                                                   |
|   DIAGNOSTIC FEATURE               DIABETIC KETOACIDOSIS (DKA)     HYPEROSMOLAR HYPERGLYCEMIC     |
|                                                                    STATE (HHS)                    |
|   ---------------------------------------------------------------------------------------------   |
|   Typical Patient Population       Type 1 DM (can occur in T2DM)   Type 2 DM (Frail / Elderly)    |
|   Speed of Clinical Onset          Rapid (< 24 hours)              Insidious (Days to Weeks)      |
|   Plasma Glucose Level             250 to 600 mg/dL                >= 600 mg/dL (frequently >1000)|
|   Arterial / Venous pH             < 7.30 (Severe < 7.00)          > 7.30                         |
|   Serum Bicarbonate (HCO3-)        < 18 mEq/L (Severe < 10 mEq/L)  > 18 mEq/L                     |
|   Urine / Serum Ketones            Strongly Positive (3+)          Negative or Trace              |
|   Serum Beta-hydroxybutyrate       Markedly Elevated (>3.0 mmol/L) Normal or Mildly Elevated      |
|   Effective Serum Osmolality       Variable (< 320 mOsm/kg)        > 320 mOsm/kg                  |
|   Serum Anion Gap                  Elevated (> 12 mEq/L)           Normal or Mildly Elevated      |
|   Mental Status Alteration         Alert to Stuporous              Profound Stupor / Coma         |
|   Mortality Rate                   1 - 3%                          10 - 20%                       |
+---------------------------------------------------------------------------------------------------+

Critical Management Algorithms for Acute Hyperglycemic Emergencies:

1. Fluid Resuscitation: Isotonic $0.9%\text{ NaCl}$ at $1,000\text{--}1,500\text{ mL/hr}$ during the first hour. When serum sodium is corrected ($[\text{Na}^+] + 0.016 \times [\text{Glucose} - 100]$), switch to $0.45%\text{ NaCl}$ if corrected sodium is normal or elevated.
2. Potassium Repletion (The Absolute Rule): Check serum potassium before administering insulin. If serum $\mathbf{K^+ < 3.3\text{ mEq/L}}$, HOLD INSULIN and administer IV potassium chloride ($20\text{--}30\text{ mEq/hr}$) until $K^+ > 3.3\text{ mEq/L}$ to prevent fatal cardiac arrest from insulin-induced intracellular potassium shifting. If $K^+$ is 3.3–5.2 mEq/L, give potassium with IV fluids and start insulin. If $K^+ > 5.2\text{ mEq/L}$, start insulin without potassium but monitor $K^+$ every 2 hours.
3. Insulin Administration: IV Regular insulin continuous infusion ($0.1\text{ units/kg/hr}$ or $0.14\text{ units/kg/hr}$ without bolus). When blood glucose reaches $200\text{ mg/dL}$ in DKA or $300\text{ mg/dL}$ in HHS, add $5%\text{ Dextrose}$ to IV fluids and decrease insulin infusion to $0.02\text{--}0.05\text{ units/kg/hr}$ to prevent cerebral edema while continuing until ketoacidosis resolves (closure of anion gap and $\text{HCO}_3^- \ge 18$).

---

8. Board-Yield Summary & Clinical Pearls

+---------------------------------------------------------------------------------------------------+
|                                 ANCC AGPCNP CLINICAL EXAM PEARLS                                  |
|                                                                                                   |
|   - Cardiorenal Protection is Independent of Baseline HbA1c: In patients with established ASCVD,  |
|     Heart Failure (HFrEF/HFpEF), or CKD (UACR >=30 or eGFR 20-60), ALWAYS add an SGLT2i or GLP-1 RA|
|     with demonstrated outcome trials (EMPA-REG, DAPA-HF, CREDENCE, LEADER) regardless of A1c.     |
|                                                                                                   |
|   - SGLT2i Renal Threshold: SGLT2 inhibitors lose their glycemic/glucose-lowering efficacy when   |
|     eGFR <45 mL/min, BUT retain robust nephroprotective and cardiovascular failure benefits down  |
|     to eGFR 20 mL/min. NEVER discontinue an SGLT2i simply because eGFR dropped to 30 mL/min!      |
|                                                                                                   |
|   - Metformin eGFR Cutoffs: eGFR >=45 (Full dose, 2000 mg/day); eGFR 30-44 (Max dose 1000 mg/day;|
|     do not initiate new therapy); eGFR <30 (Absolute Contraindication; discontinue immediately).  |
|                                                                                                   |
|   - Incretin Rules: NEVER combine GLP-1 RA + DPP-4i (no additive glycemic benefit; redundant).    |
|     Linagliptin is the ONLY DPP-4i that requires NO renal dose reduction.                         |
|                                                                                                   |
|   - 3:00 AM Blood Glucose Rule: 3:00 AM High = Dawn Phenomenon (Increase bedtime basal insulin);  |
|     3:00 AM Low = Somogyi Effect (Decrease bedtime basal insulin or give bedtime snack).          |
+---------------------------------------------------------------------------------------------------+